Solrikitug Clears Phase 2 Trial in Eosinophilic Esophagitis
Uniquity Bio reported positive topline Phase 2 results on Tuesday, November 17, 2026, for solrikitug in adults with eosinophilic esophagitis. In the randomized, double-blind, placebo-controlled ALAMERE trial, every dose tested beat placebo on both co-primary endpoints at week 24. Placebo-corrected histologic remission rates ran from 69 to 76 percent, and swallowing symptoms improved by 8.8 to 12.6 points more than placebo. The results are topline only, and the company hasn't published the trial's patient count or full data set.
Edited and fact-checked by Stephen Sprague
A Phase 3 trial planned for the first quarter of 2027 is the test that counts. The FDA has agreed that one pivotal trial, with ALAMERE as confirmatory evidence, could support a biologics license application.
At the University of North Carolina's esophageal diseases center, Dr. Evan Dellon enrolled patients whose swallowing had narrowed to a daily calculation. His site was one of the centers in ALAMERE, the Phase 2 trial Uniquity Bio reported on Tuesday.
Solrikitug is a monoclonal antibody that targets thymic stromal lymphopoietin, or TSLP, a signal the company describes as central to the allergic inflammation behind eosinophilic esophagitis. Patients in ALAMERE received it as an injection under the skin every four weeks, at one of three doses: 125 milligrams, 250 milligrams, or 500 milligrams.
The trial had two co-primary endpoints at week 24. One counted histologic remission, judged by eosinophil levels in esophageal tissue. The other tracked change in dysphagia symptoms, the difficulty and discomfort of swallowing, on the Dysphagia Symptom Questionnaire.
Every dose cleared both endpoints against placebo. Placebo-corrected histologic remission rates ran from 69 to 76 percent across the three doses, with p values below 0.001. Dysphagia scores fell by an extra 8.8 to 12.6 points beyond placebo, and the company said the drug was well tolerated with a favorable safety profile.
For a patient, those endpoints describe two different things. The tissue count is what a pathologist sees on a biopsy slide. The symptom score is whether food still sticks on the way down at dinner, and the trial required the drug to move both at once.
Eosinophilic esophagitis is chronic inflammation of the esophagus, triggered by an allergic immune response. Uniquity estimates that it affects about 470,000 people in the United States, and its prevalence has risen roughly fivefold since 2009. Left to run, the condition can progress to fibrosis and strictures, and treatment options remain extremely limited.
The limits of Tuesday's release are plain. It's a topline announcement, not a full data set. The company didn't state how many patients ALAMERE enrolled, and it hasn't presented the complete results yet. Uniquity says full results will go to a medical congress at a future date, and participants are still being tracked out to 52 weeks for durability and safety.
The next step is already scheduled. Uniquity plans a pivotal Phase 3 trial in the first quarter of 2027, and it says the FDA has agreed that the single pivotal study, together with ALAMERE as confirmatory evidence, could provide the clinical evidence for a planned biologics license application. The company is also nearing completion of Phase 2 trials of solrikitug in asthma and chronic obstructive pulmonary disease, and the drug was in-licensed from Merck & Co., Inc.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.